Human Biology Division, Fred Hutch
Clinical Research Division, Fred Hutch
Dr. Supriya “Shoop” Saha researches a deadly and difficult-to-detect form of liver cancer called intrahepatic cholangiocarcinoma, or ICC. There are currently no personalized therapies for ICC. Dr. Saha’s goal is to deeply understand ICC so he can develop targeted treatments as well as effective strategies to diagnose the disease early and even prevent its occurrence. He has created a unique set of preclinical models to reveal how this disease develops and pinpoint its therapeutic weaknesses. Using these models, Dr. Saha outlined how alterations in a gene that is commonly mutated in ICC but not in other closely related cancers may push liver cells down the path toward cancer. Dr. Saha has already identified a promising targeted drug candidate for ICC that is being tested in people. He also studies how different types of ICC tumors acquire drug resistance — and how to counteract this to produce better treatments. In addition to running a laboratory, Dr. Saha is a medical oncologist with a clinical interest in liver cancer, particularly cholangiocarcinoma and hepatocellular carcinoma.
University of Washington School of Medicine
B.A., Biochemical Sciences, Harvard University, Cambridge, 2001
M.D., Ph.D., David Geffen School of Medicine at UCLA, 2008
Residency in Internal Medicine, Brigham and Women’s Hospital, Boston, 2010
Fellowship in Medical Oncology, Dana-Farber/Harvard Cancer Center, 2014
—Dr. Supriya Saha
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email email@example.com or call 206.667.2210.